BLIS Technologies Ltd (NZX: BLT), developer and manufacturer of BLIS K12, a new generation of advanced probiotic for the prevention of upper airways infection including bacterial sore throats, prevention of tooth and gum disease and treatment of chronic bad breath, announced yesterday that it has completed a formal marketing and distribution agreement with Frutarom, USA.

Under the terms of the agreement, Frutarom USA will be responsible for all sales and marketing, warehousing and distribution activities in North America, while BLIS Technologies remains focused on further product development efforts and activities with its key research partner, The University of Otago (New Zealand)

BLIS K12 is the world’s only probiotic specifically designed to protect the entire oral cavity including the throat, mouth gums and teeth and under certain circumstances it has even been shown to protect the nasal sinus from infection. BLIS K12 is an advanced probiotic because unlike other probiotic organisms BLIS K12 will produce a bacteriocin when it is under threat from a potential pathogen. This makes BLIS K12 hundreds of times more effective than a traditional antiseptic throat lozenge.

The BLIS K12 advanced probiotic from BLIS Technologies Ltd will be officially unveiled on the Frutarom stand at the Supply Side West show in Las Vegas on Oct 23rd 2008.

Mr. Laurent Leduc, VP USA Health Division of Frutarom USA said “This is a significant opportunity for us to expand our business around a product with both an exceptional safety profile and excellent record of clinical validation for its effectiveness in preventing many common infections of the upper airways and oral cavity.”

“The great thing about BLIS K12,” Mr. Leduc said, “is that it has no peers in the market. This product is unique and with the patents around it, it will likely remain that way for a long time”

Dr Barry Richardson, Chief Executive of BLIS Technologies Ltd also indicated that he was very happy with the agreement between BLIS Technologies and Frutarom, USA. Dr Richardson said “Frutarom is a very proactive company and have already secured orders for BLIS K12, even before the ink was dry.” “Frutarom USA is very important to us because it represents further expansion of our commercial development for BLIS Technologies and it builds on our existing research relationships with Nestle Nutrition in Switzerland.

About Frutarom
Established in 1933, the Frutarom Group is a rapidly growing global flavor and fine ingredients company. Frutarom develops, manufactures and markets an extensive variety of high quality flavors and natural fine ingredients for customers in the food, beverage, flavor, fragrance, pharmaceutical, nutraceutical, food additive, and cosmetic industries. Frutarom's 20,000 products are sold to more than 10,000 customers in 120 countries around the world. The Frutarom Group has 1,500 employees worldwide and manufacturing facilities in Europe, North America, Israel and Asia.

Frutarom operates through two divisions:
• Flavors Division, which develops, produces and markets flavor compounds and food systems.
• Fine Ingredients Division, which develops, produces and markets natural flavor extracts, functional food ingredients, natural pharmaceutical/nutraceutical extracts, specialty essential oils, citrus products and aroma chemicals.

Frutarom Industries Ltd. is a public company whose stock is listed on the Tel Aviv and London Stock Exchanges. As of January 1, 2003 Frutarom has been included in the Tel Aviv 100 Index.
For further information, visit the website: www.frutarom.com

About BLIS Technologies
BLIS Technologies was formed in June 2000 to pursue the commercialization of probiotics, which produce natural antibacterial peptides that are able to kill or control the growth of other closely related bacteria. The first such probiotic, which BLIS Technologies developed is a micro-organism called Streptococcus salivarius, “BLIS K12” This organism produces two antibacterial peptides named Salivaricin A and B. Both Salivaricin A & B are referred to as a “BLIS” (or Bacteriocin Like Inhibitory Substances), hence the Company's name BLIS Technologies Limited. BLIS Technologies acquired from Otago University of New Zealand, the extensive collection of BLIS producing organisms gathered by Professor John Tagg over more than 20 years.
For further information, visit the website: www.blis.co.nz.co